Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 414

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

Radiotheranostics in oncology: current challenges and emerging opportunities

Open access
Bodei, Lisa, Herrmann, Ken, Schöder, Heiko, Scott, Andrew M., Lewis, Jason S.·2022·Nature Reviews Clinical Oncology

Abstract

Structural imaging remains an essential component of diagnosis, staging and response assessment in patients with cancer; however, as clinicians increasingly seek to noninvasively investigate tumour phenotypes and evaluate functional and molecular responses to therapy, theranostics — the combination of diagnostic imaging with targeted therapy — is becoming more widely implemented. The field of radiotheranostics, which is the focus of this Review, combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, which involves the use of small molecules, peptides and/or antibodies as carriers for therapeutic radionuclides, typically those emitting α-, β- or auger-radiation. The exponential, global expansion of radiotheranostics in oncology stems from its potential to target and eliminate tumour cells with minimal adverse effects, owing to a mechanism of action that differs distinctly from that of most other systemic therapies. Currently, an enormous opportunity exists to expand the number of patients who can benefit from this technology, to address the urgent needs of many thousands of patients across the world. In this Review, we describe the clinical experience with established radiotheranostics as well as novel areas of research and various barriers to progress. Radiotheranostics enables the clinician to image and then target lesions using the same probe. Despite this appealing potential, interest in the field of radiotheranostics has long been constrained by a lack of expertise, high infrastructure costs and the availability of non-radioactive alternative approaches. Nonetheless, several recent successes have led to renewed research interest. In this Review, the authors summarize the current challenges and opportunities in this rapidly emerging area. Radiotheranostics combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, typically with radionuclides that emit α-, β- or auger-radiation. The exponential, global expansion of radiotheranostics in oncology stems from the potential to target and eliminate tumour cells with minimal adverse effects owing to a mechanism of action that is distinctly different from that of most other systemic therapies. Approvals of new radiotheranostic agents such as 177Lu-DOTATATE and 177Lu-PSMA-617 alongside the availability of companion diagnostic agents (such as 68Ga-DOTATATE and 68Ga-PSMA-11, respectively) have driven a resurgence of interest in the field that is driving numerous clinical trials testing novel radiotheranostics. Novel and potentially clinically important radiotheranostic approaches are expanding the range of targets to include those present in the tumour microenvironment, such as blood vessels, cancer-associated fibroblasts, the stromal matrix and immune cells. Although access to radiotheranostics is expanding, challenges such as lack of isotope availability, shortages of trained personnel, regulatory burdens and costs might all limit the extent of global dissemination. Radiotheranostics combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, typically with radionuclides that emit α-, β- or auger-radiation. The exponential, global expansion of radiotheranostics in oncology stems from the potential to target and eliminate tumour cells with minimal adverse effects owing to a mechanism of action that is distinctly different from that of most other systemic therapies. Approvals of new radiotheranostic agents such as 177Lu-DOTATATE and 177Lu-PSMA-617 alongside the availability of companion diagnostic agents (such as 68Ga-DOTATATE and 68Ga-PSMA-11, respectively) have driven a resurgence of interest in the field that is driving numerous clinical trials testing novel radiotheranostics. Novel and potentially clinically important radiotheranostic approaches are expanding the range of targets to include those present in the tumour microenvironment, such as blood vessels, cancer-associated fibroblasts, the stromal matrix and immune cells. Although access to radiotheranostics is expanding, challenges such as lack of isotope availability, shortages of trained personnel, regulatory burdens and costs might all limit the extent of global dissemination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-022-00652-y

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 125 references

Cited by

See all 414

Metadata

Authors
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S.
Venue
Nature Reviews Clinical Oncology
Published
2022-06-20
Volume
19
Issue
8
Pages
534-550
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4283163361
Cited by
414
References
125
FWCI
16.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiotheranostics in oncology: current challenges and emerging opportunities. https://app.cochat.ai/papers/10.1038/s41571-022-00652-y
The paper
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022). Radiotheranostics in oncology: current challenges and emerging opportunities. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00652-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.